Pith. sign in

REVIEW 4 major objections 6 minor 99 references

Progress of the anti-obesity of Berberine

T0 review · 4 major / 6 minor · reviewed 2026-08-10 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read Berberine emerges as a multi-path, safe anti-obesity candidate, a new review argues.

desk verdict Useful mechanistic digest of berberine's anti-obesity potential, but the clinical claim rests on two under-powered trials and the safety conclusion ignores the review's own adverse-event data. read the letter →

arxiv 2501.02282 v1 pith:25JKNQSJ submitted 2025-01-04 q-bio.BM

Kong Yue , Yang haokun , Nie Rong , Zhang Xuxiang , Zhang Hongtao , Nian Xin This is my paper · ORCID
classification q-bio.BM
keywords berberineobesityanti-obesitymechanismsbioavailabilitygutmicrobiotaadiposetissuebrowningclinicaltrialsnaturalproducts
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This review assembles the case that berberine, a natural alkaloid from plants like Coptis chinensis, is an effective and safe anti-obesity agent backed by multiple preclinical studies and two small human trials. It argues that berberine acts through several converging mechanisms: suppressing fat-cell formation, converting white fat to energy-burning beige fat, lowering blood lipids, reshaping gut bacteria, and calming adipose tissue inflammation. The review also claims that the drug's main weakness—less than 1% oral bioavailability in rats—can be overcome with new formulations, co-crystals, and derivatives that have already shown improved absorption and efficacy in animal models. A sympathetic reader would take this as a strong evidence-based rationale for advancing berberine into better-designed human obesity trials.

What carries the argument

The central objects carrying the argument are the molecular circuits of adipogenesis and energy expenditure: the PPAR-γ/C/EBP-α transcriptional cascade that berberine suppresses, the UCP1-centered thermogenic program (activated through AMPK-PGC-1α, PRDM16, SIRT1, FGF21, and GDF15) that it potentiates, the LDLR and SREBP2/CYP7A1 lipid-clearance pathways it up-regulates, the gut-microbiota–GLP-1 axis it boosts via TAS2R bitter-taste receptors in tuft cells, and the adipose tissue macrophage polarization switch (M1 to M2) it drives. Around these, the review organizes bioavailability-enhancement strategies: co-crystals, nanoemulsions, cell-membrane-coated nanoparticles, and derivatives that improve absorption or evade first-pass metabolism.

What would settle it

A randomized, placebo-controlled trial enrolling at least 200 adults with obesity (BMI ≥ 30), randomizing them to 1.5 g/day berberine versus placebo for 12 months with body weight change as the primary endpoint, and showing no significant difference in weight loss or fat mass, would directly overturn the review's central clinical claim.

Watch

Extended reading notes

Core claim

The paper's central claim is that berberine and its metabolites constitute a viable natural alternative for obesity management, effective through a network of distinct molecular pathways. Clinically, the review points to Hu et al. showing a 23% reduction in triglycerides and 12.2% reduction in total cholesterol in obese subjects given 1.5 g/day for 12 weeks, and to Bandala et al. reporting significant decreases in body weight, BMI, body fat percentage, and visceral fat in obese patients taking 500 mg three times daily for three months. Mechanistically, the review integrates evidence that berberine down-regulates adipogenic transcription factors (PPAR-γ, C/EBP-α), activates thermogenesis via AMPK/PGC-1α, UCP1, PRDM16, SIRT1, FGF21, and GDF15, up-regulates hepatic LDL receptor expression, promotes lacteal junction zippering to block dietary fat absorption, modulates gut microbiota to boost GLP-1 secretion, and shifts adipose tissue macrophages toward the anti-inflammatory M2 phenotype. Finally, it argues that the bioavailability hurdle is being addressed: a berberine-ibuprofen co-crystal showed threefold higher bioavailability and better anti-obesity effects in db/db mice, dihydroberberine produced far higher plasma berberine levels than native berberine in a human pilot, and nanoemulsions and derivative compounds (tetrahydroberberrubine, oxyberberine) show enhanced potency.

Load-bearing premise

The review's confidence in berberine's clinical anti-obesity effect rests on a handful of short-term human trials that were not designed with weight loss as the primary endpoint, and on rodent studies whose fat biology differs from humans.

Editorial extensions

If this is right

  • If the review's synthesis holds, berberine could enter head-to-head trials against orlistat or GLP-1 receptor agonists as a cheaper, orally available alternative with a different side-effect profile.
  • The baseline gut-microbiota markers (Alistipes and Blautia) identified as predictors of berberine's cholesterol-lowering efficacy could be developed into a patient-selection test for obesity therapy.
  • The mechanistic evidence that berberine induces GDF15 and FGF21 suggests it may synergize with newer incretin-based drugs that target appetite and energy expenditure through separate pathways.
  • The co-crystal and dihydroberberine data imply that simple chemical modifications—not just advanced delivery systems—can transform berberine's pharmacokinetics enough for clinical use.
  • If the anti-inflammatory and M2-polarizing effects are confirmed in humans, berberine could be studied for obesity-related complications such as insulin resistance and atherosclerosis, not just weight loss.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • My inference: the TAS2R/bitter-taste mechanism described in the paper implies that taste-masking formulations (like the macrocycle encapsulation it cites) could inadvertently blunt the very gut signaling that drives GLP-1 release; a formulation that preserves receptor activation while masking bitterness would be a worthwhile test.
  • My inference: because the two human trials were short (12 weeks and 3 months) and not powered for obesity as a primary endpoint, the review's clinical claim would be dramatically strengthened or falsified by a single randomized trial with a 12-month horizon and weight loss as the primary outcome.
  • My inference: the lacteal-zippering pathway (RhoA/ROCK1) offers a druggable target independent of gut absorption, meaning even low-bioavailability berberine might work locally in the intestine—a hypothesis the review's authors do not explicitly draw out.
  • My inference: if dihydroberberine's roughly 20-fold higher plasma exposure in the pilot study reproduces, then historical negative or weak results with native berberine may need re-interpretation, and the field should consider standardizing pharmacokinetic equivalents rather than milligram doses.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 6 minor

Summary. This review assembles preclinical and clinical literature on berberine (BBR) and its metabolites as anti-obesity agents. It summarizes mechanisms including inhibition of adipogenesis, browning of white adipose tissue, lipid metabolism regulation, gut microbiota modulation, adipose tissue macrophage polarization, and inflammation reduction, and it surveys bioavailability-enhancement strategies such as rational combinations, co-crystals, delivery systems, and derivatives. The central claim is that BBR and its metabolites are effective and safe anti-obesity agents, supported mainly by in vitro and rodent studies plus two human trials described in §2.1.2.

Significance. If the clinical claims are properly qualified, the review is a useful and reasonably current narrative overview of BBR's preclinical anti-obesity mechanisms and formulation strategies. Its strength is the breadth of mechanistic coverage and the recent literature cited (including 2023–2024 publications). The review does not provide machine-checked proofs, but it does offer a structured collection of evidence tables and a clearly organized mechanism-by-mechanism discussion. The main value is as a reference for researchers interested in BBR's biology and formulation; its clinical conclusions, however, are not commensurate with the evidence presented.

major comments (4)
  1. [§2.1.2, Table 2] The clinical evidence for BBR's anti-obesity effect rests on only two studies: Hu et al. [55], a lipid-lowering trial that reports 'mild weight loss (average 5 lb/subject)' as a secondary observation, and Bandala et al. [56], a 3-month comparative study. Neither trial lists body-weight change as a pre-specified primary endpoint, and the review does not report effect sizes, confidence intervals, or dropout data for either. The abstract and §2.1.2 nevertheless state that these data 'demonstrated the anti-obesity effect of BBR.' This is a load-bearing overstatement. The authors should either present the quantitative outcomes with explicit caveats about the secondary nature of the weight-loss findings, or soften the clinical conclusion accordingly.
  2. [§2.2 (Safety)] The safety conclusion is internally inconsistent with the data reported in the same section. The text states that Bandala et al. observed nausea in 20%, constipation in 16%, and hemorrhoidal bleeding in 28% of patients, and that long-term BBR use causes constipation, yet concludes 'BBR is a safe medicinal plant ingredient.' A balanced safety assessment should weigh these adverse-event rates against placebo, discuss severity and duration, and avoid a blanket safety claim based on a single short-term RCT. Also, the reference cited for the 'no adverse events' Phytosome trial is [58], which is an umbrella review, not the primary randomized trial described; this citation needs correction.
  3. [References [47] and [58]] Several citations do not match the claims they support. In the Introduction, the statement that first-pass metabolism contributes to BBR's low oral bioavailability is cited to [47] (Gupta et al., a study of glucocorticoid-induced hyperglycemia), which does not address BBR bioavailability. In §2.2, the described randomized Phytosome trial is cited to [58], which is a broader umbrella review, not the trial itself. These misattributions undermine verifiability and should be corrected.
  4. [§5, Summary] The Summary states that 'BBR has significant potential as a new drug for treating metabolic syndrome and hereditary endocrine diseases.' The first part is supported by the review's metabolic content, but 'hereditary endocrine diseases' is not discussed anywhere in the manuscript and is not supported by the cited evidence. This sentence should be removed or replaced with a claim that the review actually supports.
minor comments (6)
  1. [Abstract] The sentence 'Berberine (BBR) and its metabolites, known for their multiple pharmacological effects.' is a fragment; it should be merged with the following sentence or completed grammatically.
  2. [Throughout] There are numerous typographical errors, including 'clinical trail' for 'clinical trial', 'tratment' for 'treatment', 'aforementions' for 'aforementioned', 'bomimetic' for 'biomimetic', 'C58BL/6' for 'C57BL/6', and 'BBB' used for berberrubine (which is elsewhere called M1). These should be corrected throughout.
  3. [Table 2] The clinical results are reported only as p-values and qualitative statements. Adding effect sizes (e.g., mean change in body weight, BMI, with 95% CIs) would allow readers to judge clinical meaningfulness.
  4. [§2.1.1, Table 1] The preclinical table lists 'Gupta et al.' with a study on dexamethasone-induced hyperglycemia and fat mass; this study's primary focus is glucose metabolism, not obesity, so its inclusion as a central anti-obesity preclinical trial should be justified.
  5. [§6 Declarations] The Declarations section has duplicate numbering ('(2)' appears twice) and inconsistent formatting; this should be cleaned up.
  6. [References] Reference [11] contains the garbled text 'WolWolfe BM' and should be corrected to 'Wolfe BM'. Also, a systematic search strategy or statement that this is a narrative review with no systematic search would clarify the scope and reduce the impression of selection bias.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: the paper is a narrative review whose claims are summaries of cited external studies, with no derivation, fitted parameters, or self-citation chain that reduces to its own inputs.

full rationale

This manuscript is a literature review, not a derivation or modeling paper. It contains no equations, no fitted parameters, and no quantities that are defined in terms of one another. The anti-obesity claims are presented as summaries of cited preclinical and clinical studies (e.g., Xu et al. [48], Hu et al. [55], Bandala et al. [56]), and the mechanistic sections attribute findings to named primary sources rather than deriving them within the review. The review explicitly acknowledges its own evidentiary limits: 'Most experiments have been conducted in rodents, whose fat distribution and metabolism differ from those of humans' and 'these trials are not specifically designed for obesity treatment.' These statements are limitations of evidence strength and generalizability, not circular reasoning. No self-citation is used as load-bearing support for a uniqueness claim or an ansatz; the review does not invoke any privileged prior result by the same authors to close an argument. The closest concern—that the clinical conclusion relies on two short-term trials with secondary weight endpoints—is a question of evidence quality and potential selection bias, which is outside the definition of circularity used here. Therefore, the appropriate finding is no significant circularity, with a score of 0.

Assumptions & free parameters 0 free parameters · 2 assumptions · 0 invented entities

The review introduces no free parameters, no invented entities, and no mathematical axioms. Its conclusions depend on the reliability of the cited literature and on the translatability of rodent findings to humans.

assumptions (2)
  • domain assumption The cited primary studies are reported accurately and their results are internally valid.
    The review's conclusions rest entirely on the summarized preclinical and clinical studies; if any of these studies are flawed or misreported, the synthesis is compromised.
  • domain assumption Rodent models of HFD-induced obesity are representative of human obesity pathophysiology.
    Most mechanisms are derived from mouse/rat studies; the review itself notes that fat distribution and metabolism differ between rodents and humans (Section 5), so the mechanistic claims may not transfer.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Progress of the anti-obesity of Berberine." pith.science (2026). https://pith.science/paper/25JKNQSJ

@misc{pith2026250102282,
  author       = {Pith},
  title        = {Pith review of: Progress of the anti-obesity of Berberine},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/25JKNQSJ}},
  note         = {Machine review of arXiv:2501.02282}
}
read the original abstract

Obesity is defined as the excessive accumulation or abnormal distribution of body fat. According to data from World Obesity Atlas 2024, the increase in prevalence of obesity has become a major worldwide health problem in adults as well as among children and adolescents. Although an increasing number of drugs have been approved for the treatment of obesity in recent years, many of these drugs have inevitable side effects which have increased the demand for new safe, accessible and effective drugs for obesity and prompt interest in natural products. Berberine (BBR) and its metabolites, known for their multiple pharmacological effects. Recent studies have emphatically highlighted the anti-obesity benefits of BBR and the underlying mechanisms have been gradually elucidated. However, its clinical application is limited by poor oral absorption and low bioavailability. Based on this, this review summarizes current research on the anti-obesity effects of BBR and its metabolites, including advancements in clinical trail results, understanding potential molecular mechanisms and absorption and bioavailability. As a natural compound derived from plants, BBR holds potential as an alternative approach for managing obesity.

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

99 extracted references · 78 canonical work pages

  1. [55]

    【114】Wang TT, Yu LL, Zheng JM, Han XY, Jin BY, Hua CJ, Chen YS, Shang SS, Liang YZ, Wang JR

    PMID: 31243391. 【114】Wang TT, Yu LL, Zheng JM, Han XY, Jin BY, Hua CJ, Chen YS, Shang SS, Liang YZ, Wang JR. Berberine Inhibits Ferroptosis and Stabilizes Atherosclerotic Plaque through NRF2/SLC7A11/GPX4 Pathway. Chin J Integr Med. 2024 Oct;30(10):906-916. doi: 10.1007/s11655-024-3666-z. Epub 2024 Aug

    work page doi:10.1007/s11655-024-3666-z 2024

  2. [56]

    【115】Hong Y, Feng J, Dou Z, Sun X, Hu Y, Chen Z, Liu L, Xu H, Du M, Tang P, Liu X, Zhang Y

    PMID: 39167283. 【115】Hong Y, Feng J, Dou Z, Sun X, Hu Y, Chen Z, Liu L, Xu H, Du M, Tang P, Liu X, Zhang Y. Berberine as a novel ACSL4 inhibitor to suppress endothelial ferroptosis and atherosclerosis. Biomed Pharmacother. 2024 Aug;177:117081. doi: 10.1016/j.biopha.2024.117081. Epub 2024 Jul

    arXiv 2024

  3. [58]

    【121】Abidi P, Zhou Y, Jiang JD, Liu J

    PMID: 25196457. 【121】Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2170-6. doi: 10.1161/01.ATV.0000181761.16341.2b. Epub 2005 Aug

    work page arXiv 2005

  4. [47]

    【94】Himms-Hagen J, Melnyk A, Zingaretti MC, Ceresi E, Barbatelli G, Cinti S

    PMID: 22796012; PMCID: PMC3402601. 【94】Himms-Hagen J, Melnyk A, Zingaretti MC, Ceresi E, Barbatelli G, Cinti S. Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes. Am J Physiol Cell Physiol. 2000 Sep;279(3):C670-81. doi: 10.1152/ajpcell.2000.279.3.C670. PMID: 10942717. 【95】Barbatelli G, Murano I, Madsen L, Hao Q,...

    arXiv

  5. [1]

    Epidemiology of Obesity

    【1】Sørensen TIA, Martinez AR, Jørgensen TSH. Epidemiology of Obesity. Handb Exp Pharmacol. 2022;274:3-27. doi: 10.1007/164_2022_581. PMID: 35419622. 【2】Koliaki C, Dalamaga M, Liatis S. Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten? Curr Obes Rep. 2023 Dec;12(4):514-527. doi: 10.1007/s13679-023-00527-y...

    work page doi:10.1007/164_2022_581 2022

  6. [2]

    2023 Dec;12(4):528

    Erratum in: Curr Obes Rep. 2023 Dec;12(4):528. doi: 10.1007/s13679-023-00533-0. PMID: 37779155; PMCID: PMC10748771. 【3】World Obesity Federation. World Obesity Atlas

    work page doi:10.1007/s13679-023-00533-0 2023

  7. [3]

    Epub ahead of print

    doi: 10.1002/phar.4607. Epub ahead of print. PMID: 39225417. 【26】Valenzano A, Tartaglia N, Ambrosi A, Tafuri D, Monda M, Messina A, Sessa F, Campanozzi A, Monda V, Cibelli G, Messina G, Polito R. The Metabolic Rearrangements of Bariatric Surgery: Focus on Orexin-A and the Adiponectin System. J Clin Med. 2020 Oct 16;9(10):3327. doi: 10.3390/jcm9103327. PMI...

    work page doi:10.1002/phar.4607

  8. [4]

    【34】Sachdeva A, Dalton M, Lees T

    PMID: 39277295. 【34】Sachdeva A, Dalton M, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2018 Nov 3;11(11):CD001484. doi: 10.1002/14651858.CD001484.pub4. PMID: 30390397; PMCID: PMC6477662. 【35】Hirasawa N, Shimizu Y, Haginoya A, Soma Y, Watanabe G, Takehara K, Tokeji K, Mataki Y, Ishii R, Hada Y....

    work page doi:10.1002/14651858.cd001484.pub4 2018

Show all 99 references
  1. [5]

    【116】Zwick RK, Guerrero-Juarez CF, Horsley V, Plikus MV

    PMID: 38971008. 【116】Zwick RK, Guerrero-Juarez CF, Horsley V, Plikus MV. Anatomical, Physiological, and Functional Diversity of Adipose Tissue. Cell Metab. 2018 Jan 9;27(1):68-83. doi: 10.1016/j.cmet.2017.12.002. PMID: 29320711; PMCID: PMC6050204. 【117】Recinella L, Orlando G, ...

    2018

  2. [6]

    【55】Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, Downey T, Bohlen K, Callahan L, Munson V, Jahnke M, Marshall LL, Nelson K, Huizenga P, Hansen R, Soundy TJ, Davies GE

    PMID: 38711201. 【55】Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, Downey T, Bohlen K, Callahan L, Munson V, Jahnke M, Marshall LL, Nelson K, Huizenga P, Hansen R, Soundy TJ, Davies GE. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine. 2012 Jul 15...

    2012 doi

  3. [7]

    【54】Du J, Zhu Y, Yang X, Geng X, Xu Y, Zhang M, Zhang M

    PMID: 38176265. 【54】Du J, Zhu Y, Yang X, Geng X, Xu Y, Zhang M, Zhang M. Berberine attenuates obesity-induced insulin resistance by inhibiting miR-27a secretion. Diabet Med. 2024 Jul;41(7):e15319. doi: 10.1111/dme.15319. Epub 2024 May

    2024 doi

  4. [8]

    【126】DeBose-Boyd RA, Ye J

    PMID: 27932556; PMCID: PMC5267522. 【126】DeBose-Boyd RA, Ye J. SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond. Trends Biochem Sci. 2018 May;43(5):358-368. doi: 10.1016/j.tibs.2018.01.005. Epub 2018 Feb

    2018 doi

  5. [9]

    【72】Kiwaki K, Novak CM, Hsu DK, Liu FT, Levine JA

    PMID: 25303959. 【72】Kiwaki K, Novak CM, Hsu DK, Liu FT, Levine JA. Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. Obesity (Silver Spring). 2007 Jan;15(1):32-9. doi: 10.1038/oby.2007.526. PMID: 17228029. 【73】Krautbauer S, Eisinge...

    2007 doi

  6. [10]

    【7】Popa MM, Sirbu AE, Malinici EA, Copaescu C, Fica S

    PMID: 28489290. 【7】Popa MM, Sirbu AE, Malinici EA, Copaescu C, Fica S. Obesity-related renal dysfunction: gender-specific influence of visceral adiposity and early impact of metabolic and bariatric surgery. Front Endocrinol (Lausanne). 2024 Oct 14;15:1440250. doi: 10.3389/fend...

    2024

  7. [11]

    【122】Singh AB, Li H, Kan CF, Dong B, Nicolls MR, Liu J

    PMID: 16100034. 【122】Singh AB, Li H, Kan CF, Dong B, Nicolls MR, Liu J. The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3' untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue. Arterioscler Thr...

    2014 doi

  8. [12]

    【39】Cicero AF, Baggioni A

    PMID: 25128422. 【39】Cicero AF, Baggioni A. Berberine and Its Role in Chronic Disease. Adv Exp Med Biol. 2016;928:27-45. doi: 10.1007/978-3-319-41334-1_2. PMID: 27671811. 【40】Qiu F, Zhu Z, Kang N, Piao S, Qin G, Yao X. Isolation and identification of urinary metabolites of berb...

    2016 doi

  9. [13]

    【30】Gagnon C, Schafer AL

    PMID: 34963509; PMCID: PMC9218004. 【30】Gagnon C, Schafer AL. Bone Health After Bariatric Surgery. JBMR Plus. 2018 May 1;2(3):121-133. doi: 10.1002/jbm4.10048. PMID: 30283897; PMCID: PMC6124196. 【31】van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after esophageal, gas...

    2018 doi

  10. [14]

    【32】Chakhtoura MT, Nakhoul NF, Akl EA, Safadi BY, Mantzoros CS, Metzendorf MI, El-Hajj Fuleihan G

    PMID: 27749997. 【32】Chakhtoura MT, Nakhoul NF, Akl EA, Safadi BY, Mantzoros CS, Metzendorf MI, El-Hajj Fuleihan G. Oral vitamin D supplementation for adults with obesity undergoing bariatric surgery. Cochrane Database Syst Rev. 2024 Oct 1;10(10):CD011800. doi: 10.1002/14651858...

    2024 doi

  11. [15]

    【108】Li C, Leng Q, Li L, Hu F, Xu Y, Gong S, Yang Y, Zhang H, Li X

    PMID: 29065221; PMCID: PMC5758394. 【108】Li C, Leng Q, Li L, Hu F, Xu Y, Gong S, Yang Y, Zhang H, Li X. Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes. Endocrinology. 2023 Feb 11;164(4):bqad035. doi: 10.1210/endocr/bqad035. PMID: 36825874. 【109】Ka...

    2023

  12. [16]

    【37】Wennerlund J, Gunnarsson U, Strigård K, Sundbom M

    PMID: 26948448. 【37】Wennerlund J, Gunnarsson U, Strigård K, Sundbom M. Acid-related complications after laparoscopic Roux-en-Y gastric bypass: risk factors and impact of proton pump inhibitors. Surg Obes Relat Dis. 2020 May;16(5):620-625. doi: 10.1016/j.soard.2020.01.005. Epub...

    2020 doi

  13. [17]

    【20】Mutoh J, Ohsawa M, Hisa H

    PMID: 24343039. 【20】Mutoh J, Ohsawa M, Hisa H. Effect of naloxone on ischemic acute kidney injury in the mouse. Neuropharmacology. 2013 Aug;71:10-8. doi: 10.1016/j.neuropharm.2013.03.001. Epub 2013 Mar

    2013 doi

  14. [18]

    【38】Choi JS, Kim JH, Ali MY, Min BS, Kim GD, Jung HA

    PMID: 32107170. 【38】Choi JS, Kim JH, Ali MY, Min BS, Kim GD, Jung HA. Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP- α and PPAR- γ . Fitoterapia. 2014 Oct;98:199-208. doi: 10.1016/j.fitote.2014.08.006. Epub 2014 Aug

    2014 doi

  15. [19]

    【21】Erken E, Altunoren O, Gungor O

    PMID: 23523991. 【21】Erken E, Altunoren O, Gungor O. Orlistat and acute kidney injury: a case report. Clin Nephrol. 2017 Mar;87 (2017)(3):157-158. doi: 10.5414/CN109029. PMID: 28177280. 【22】Colbourne JRM, Fisher OM, Mo S, Rigas GS, Talbot ML. The role of adjuvant pharmacotherap...

    2017

  16. [20]

    【29】Murtha JA, Alagoz E, Breuer CR, Finn A, Raffa SD, Voils CI, Funk LM

    PMID: 29680836. 【29】Murtha JA, Alagoz E, Breuer CR, Finn A, Raffa SD, Voils CI, Funk LM. Individual-level barriers to bariatric surgery from patient and provider perspectives: A qualitative study. Am J Surg. 2022 Jul;224(1 Pt B):429-436. doi: 10.1016/j.amjsurg.2021.12.022. Epu...

    2022 doi

  17. [21]

    【41】Guo HH, Shen HR, Wang LL, Luo ZG, Zhang JL, Zhang HJ, Gao TL, Han YX, Jiang JD

    PMID: 18703644. 【41】Guo HH, Shen HR, Wang LL, Luo ZG, Zhang JL, Zhang HJ, Gao TL, Han YX, Jiang JD. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. Biomed Pharmacother. 2023 Jul;163:114754. doi: 10.1016/j...

    2023

  18. [22]

    【42】An N, Zhang G, Li Y, Yuan C, Yang F, Zhang L, Gao Y, Xing Y

    PMID: 37094549. 【42】An N, Zhang G, Li Y, Yuan C, Yang F, Zhang L, Gao Y, Xing Y. Promising Antioxidative Effect of Berberine in Cardiovascular Diseases. Front Pharmacol. 2022 Mar 7;13:865353. doi: 10.3389/fphar.2022.865353. PMID: 35321323; PMCID: PMC8936808. 【43】Cole LK, Zhang...

    2022

  19. [23]

    【6】Bray GA, Kim KK, Wilding JPH; World Obesity Federation

    PMID: 34815532; PMCID: PMC8609996. 【6】Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May

    2017 doi

  20. [24]

    【47】Gupta M, Rumman M, Singh B, Mahdi AA, Pandey S

    PMID: 21637946; PMCID: PMC3134654. 【47】Gupta M, Rumman M, Singh B, Mahdi AA, Pandey S. Berberine ameliorates glucocorticoid-induced hyperglycemia: an in vitro and in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2024 Mar;397(3):1647-1658. doi: 10.1007/s00210-023-02703-2. Ep...

    2024 doi

  21. [25]

    【48】Xu JH, Liu XZ, Pan W, Zou DJ

    PMID: 37704773. 【48】Xu JH, Liu XZ, Pan W, Zou DJ. Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. Mol Med Rep. 2017 May;15(5):2765-2787. doi: 10.3892/mmr.2017.6321. Epub 2017 Mar

    2017

  22. [26]

    【15】Wadden TA, Webb VL, Moran CH, Bailer BA

    PMID: 29842854. 【15】Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation. 2012 Mar 6;125(9):1157-70. doi: 10.1161/CIRCULATIONAHA.111.039453. PMID: 22392863; PMCID: PMC3313649...

    2012 doi

  23. [27]

    【5】Müller TD, Blüher M, Tschöp MH, DiMarchi RD

    PMID: 32353823. 【5】Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022 Mar;21(3):201-223. doi: 10.1038/s41573-021-00337-8. Epub 2021 Nov

    2022 doi

  24. [28]

    【49】Park HJ, Jung E, Shim I

    PMID: 28447763; PMCID: PMC5428400. 【49】Park HJ, Jung E, Shim I. Berberine for Appetite Suppressant and Prevention of Obesity. Biomed Res Int. 2020 Dec 12;2020:3891806. doi: 10.1155/2020/3891806. PMID: 33415147; PMCID: PMC7752296. 【50】Wang M, Geng X, Li K, Wang Y, Duan X, Hou C...

    2020

  25. [29]

    【11】WolWolfe BM, Kvach E, Eckel RH

    PMID: 32360593. 【11】WolWolfe BM, Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. Circ Res. 2016 May 27;118(11):1844-55. doi: 10.1161/CIRCRESAHA.116.307591. PMID: 27230645; PMCID: PMC4888907. 【12】Arterburn DE, Courcoulas AP. Bariatric surgery for obe...

    2016 doi

  26. [30]

    【52】Sun S, Yang Y, Xiong R, Ni Y, Ma X, Hou M, Chen L, Xu Z, Chen L, Ji M

    PMID: 36174380. 【52】Sun S, Yang Y, Xiong R, Ni Y, Ma X, Hou M, Chen L, Xu Z, Chen L, Ji M. Oral berberine ameliorates high-fat diet-induced obesity by activating TAS2Rs in tuft and endocrine cells in the gut. Life Sci. 2022 Dec 15;311(Pt A):121141. doi: 10.1016/j.lfs.2022.1211...

    2022

  27. [31]

    【53】Wang H, Chen S, Tang Y, Nie K, Gao Y, Wang Z, Su H, Wu F, Gong J, Fang K, Dong H, Hu M

    PMID: 36341914. 【53】Wang H, Chen S, Tang Y, Nie K, Gao Y, Wang Z, Su H, Wu F, Gong J, Fang K, Dong H, Hu M. Berberine promotes lacteal junction zippering and ameliorates diet-induced obesity through the RhoA/ROCK signaling pathway. Phytomedicine. 2024 Feb;124:155268. doi: 10.1...

    2024

  28. [32]

    PMID: 22739410. 【56】Bandala C, Carro-Rodríguez J, Cárdenas-Rodríguez N, Peña-Montero I, Gómez-López M, Hernández-Roldán AP, Huerta-Cruz JC, Muñoz-González F, Ignacio-Mejía I, Domínguez B, Lara-Padilla E. Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Bod...

    doi

  29. [33]

    【59】Cui M, Li Y, Zheng T, Chen H, Wang J, Feng Y, Ye H, Dong Z, Li G

    PMID: 36999891. 【59】Cui M, Li Y, Zheng T, Chen H, Wang J, Feng Y, Ye H, Dong Z, Li G. Efficacy and Molecular Mechanism of Quercetin on Constipation Induced by Berberine via Regulating Gut Microbiota. Int J Mol Sci. 2024 Jun 5;25(11):6228. doi: 10.3390/ijms25116228. PMID: 38892...

    2024 doi

  30. [34]

    【68】Shou JW, Shaw PC

    PMID: 12426306. 【68】Shou JW, Shaw PC. Berberine Reduces Lipid Accumulation in Obesity via Mediating Transcriptional Function of PPAR δ . Int J Mol Sci. 2023 Jul 18;24(14):11600. doi: 10.3390/ijms241411600. PMID: 37511356; PMCID: PMC10380538. 【69】Zhang JW, Klemm DJ, Vinson C, L...

    2023 doi

  31. [35]

    【70】Yang DC, Tsay HJ, Lin SY, Chiou SH, Li MJ, Chang TJ, Hung SC

    PMID: 14593102. 【70】Yang DC, Tsay HJ, Lin SY, Chiou SH, Li MJ, Chang TJ, Hung SC. cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS One. 2008 Feb 6;3(2):e1540. doi: 10.1371/journal.pone.00...

    2008 doi

  32. [36]

    【74】Blasetti Fantauzzi C, Iacobini C, Menini S, Vitale M, Sorice GP, Mezza T, Cinti S, Giaccari A, Pugliese G

    PMID: 25043674. 【74】Blasetti Fantauzzi C, Iacobini C, Menini S, Vitale M, Sorice GP, Mezza T, Cinti S, Giaccari A, Pugliese G. Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis. Sci Rep. 2020 Nov 18...

    2020 doi

  33. [37]

    【76】San Martín A, Du P, Dikalova A, Lassègue B, Aleman M, Góngora MC, Brown K, Joseph G, Harrison DG, Taylor WR, Jo H, Griendling KK

    PMID: 35491999; PMCID: PMC9238585. 【76】San Martín A, Du P, Dikalova A, Lassègue B, Aleman M, Góngora MC, Brown K, Joseph G, Harrison DG, Taylor WR, Jo H, Griendling KK. Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. Am J...

    2007

  34. [38]

    【77】Thompson JA, Larion S, Mintz JD, Belin de Chantemèle EJ, Fulton DJ, Stepp DW

    PMID: 17237245. 【77】Thompson JA, Larion S, Mintz JD, Belin de Chantemèle EJ, Fulton DJ, Stepp DW. Genetic Deletion of NADPH Oxidase 1 Rescues Microvascular Function in Mice With Metabolic Disease. Circ Res. 2017 Aug 18;121(5):502-511. doi: 10.1161/CIRCRESAHA.116.309965. Epub 2017 Jul

    2017 doi

  35. [39]

    【78】Muñoz M, López-Oliva ME, Rodríguez C, Martínez MP, Sáenz-Medina J, Sánchez A, Climent B, Benedito S, García-Sacristán A, Rivera L, Hernández M, Prieto D

    PMID: 28684629; PMCID: PMC5729041. 【78】Muñoz M, López-Oliva ME, Rodríguez C, Martínez MP, Sáenz-Medina J, Sánchez A, Climent B, Benedito S, García-Sacristán A, Rivera L, Hernández M, Prieto D. Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress...

    2020

  36. [40]

    【79】Gimenez M, Schickling BM, Lopes LR, Miller FJ Jr

    PMID: 31563085; PMCID: PMC6812001. 【79】Gimenez M, Schickling BM, Lopes LR, Miller FJ Jr. Nox1 in cardiovascular diseases: regulation and pathophysiology. Clin Sci (Lond). 2016 Feb;130(3):151-65. doi: 10.1042/CS20150404. PMID: 26678171. 【80】Padgett CA, Bátori RK, Speese AC, Ros...

    2016 doi

  37. [41]

    2023 Oct;43(10):e381-e395

    Arterioscler Thromb Vasc Biol. 2023 Oct;43(10):e381-e395. doi: 10.1161/ATVBAHA.123.319476. Epub 2023 Aug

    2023 doi

  38. [42]

    【81】Uezumi A, Fukada S, Yamamoto N, Ikemoto-Uezumi M, Nakatani M, Morita M, Yamaguchi A, Yamada H, Nishino I, Hamada Y, Tsuchida K

    PMID: 37586054; PMCID: PMC10695282. 【81】Uezumi A, Fukada S, Yamamoto N, Ikemoto-Uezumi M, Nakatani M, Morita M, Yamaguchi A, Yamada H, Nishino I, Hamada Y, Tsuchida K. Identification and characterization of PDGFRα+ mesenchymal progenitors in human skeletal muscle. Cell Death D...

    2014 doi

  39. [43]

    【83】Baek JH, Kim SJ, Kang HG, Lee HW, Kim JH, Hwang KA, Song J, Chun KH

    PMID: 35029658. 【83】Baek JH, Kim SJ, Kang HG, Lee HW, Kim JH, Hwang KA, Song J, Chun KH. Galectin-3 activates PPARγ and supports white adipose tissue formation and high-fat diet-induced obesity. Endocrinology. 2015 Jan;156(1):147-56. doi: 10.1210/en.2014-1374. PMID: 25343273. ...

    2015 doi

  40. [44]

    【89】Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, Chen Q

    PMID: 29365334. 【89】Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, Chen Q. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021 Apr 26;12:653887. doi: 10.3389/fphar.2021.6538...

    2021

  41. [45]

    【91】Bartelt A, Heeren J

    PMID: 33872596; PMCID: PMC8131923. 【91】Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol. 2014 Jan;10(1):24-36. doi: 10.1038/nrendo.2013.204. Epub 2013 Oct

    2014 doi

  42. [46]

    【92】Pilkington AC, Paz HA, Wankhade UD

    PMID: 24146030. 【92】Pilkington AC, Paz HA, Wankhade UD. Beige Adipose Tissue Identification and Marker Specificity-Overview. Front Endocrinol (Lausanne). 2021 Mar 12;12:599134. doi: 10.3389/fendo.2021.599134. PMID: 33776911; PMCID: PMC7996049. 【93】Wu J, Boström P, Sparks LM, Y...

    2021

  43. [48]

    【96】Nicholls DG, Locke RM

    PMID: 20354155. 【96】Nicholls DG, Locke RM. Thermogenic mechanisms in brown fat. Physiol Rev. 1984 Jan;64(1):1-64. doi: 10.1152/physrev.1984.64.1.1. PMID: 6320232. 【97】Gong D, Lei J, He X, Hao J, Zhang F, Huang X, Gu W, Yang X, Yu J. Keys to the switch of fat burning: stimuli t...

    1984

  44. [49]

    Epub ahead of print

    doi: 10.1002/oby.24132. Epub ahead of print. PMID: 39327772. 【101】Wang B, Hu Z, Cui L, Zhao M, Su Z, Jiang Y, Liu J, Zhao Y, Hou Y, Yang X, Zhang C, Guo B, Li D, Zhao L, Zheng S, Zhao Y, Yang W, Wang D, Yu S, Zhu S, Yan Y, Yuan G, Li K, Zhang W, Qin L, Zhang W, Sun F, Luo J, Z...

  45. [50]

    【103】Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y, Yao S, Ma Q, Jin L, Yang J, Wang W, Ning G

    PMID: 38307386; PMCID: PMC10864868. 【103】Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y, Yao S, Ma Q, Jin L, Yang J, Wang W, Ning G. Berberine activates thermogenesis in white and brown adipose tissue. Nat Commun. 2014 Nov 25;5:5493. doi: 10.1038/ncomms6493. PMID: 25423280. 【...

    2014 arXiv

  46. [51]

    【105】Yao S, Yuan Y, Zhang H, Meng X, Jin L, Yang J, Wang W, Ning G, Zhang Y, Zhang Z

    PMID: 35612892. 【105】Yao S, Yuan Y, Zhang H, Meng X, Jin L, Yang J, Wang W, Ning G, Zhang Y, Zhang Z. Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. Free Radic Biol Med. 2020 Nov 1;159:66-75. doi: 10.1016/j.freeradbiomed.2020.07.028. Epub 2020 Jul

    2020 doi

  47. [52]

    【106】Wu L, Xia M, Duan Y, Zhang L, Jiang H, Hu X, Yan H, Zhang Y, Gu Y, Shi H, Li J, Gao X, Li J

    PMID: 32745766. 【106】Wu L, Xia M, Duan Y, Zhang L, Jiang H, Hu X, Yan H, Zhang Y, Gu Y, Shi H, Li J, Gao X, Li J. Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. Cell Death Dis. 2019 Jun 13;10(6):468. doi: 10.1038/s41419-019-1706-y...

    2019 doi

  48. [53]

    2018 Jan;175(2):374-387

    Br J Pharmacol. 2018 Jan;175(2):374-387. doi: 10.1111/bph.14079. Epub 2017 Dec

    2018 doi

  49. [54]

    【110】Rønn PF, Andersen GS, Lauritzen T, Christensen DL, Aadahl M, Carstensen B, Grarup N, Jørgensen ME

    PMID: 36038052. 【110】Rønn PF, Andersen GS, Lauritzen T, Christensen DL, Aadahl M, Carstensen B, Grarup N, Jørgensen ME. Abdominal visceral and subcutaneous adipose tissue and associations with cardiometabolic risk in Inuit, Africans and Europeans: a cross-sectional s tudy. BMJ...

    2020 doi

  50. [57]

    【119】Cicero AF, Rovati LC, Setnikar I

    PMID: 15531889. 【119】Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung. 2007;57(1):26-30. doi: 10.1055/s-0031-1296...

    2007 doi

  51. [59]

    【123】Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY

    PMID: 24158514; PMCID: PMC4032120. 【123】Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun. 2007 Nov 3;362(4):853-7. doi: 10.1016/j.bbrc.2007.08.060. Epub 2007 Aug

    2007 doi

  52. [60]

    2008 Aug 15;373(1):176

    Erratum in: Biochem Biophys Res Commun. 2008 Aug 15;373(1):176. PMID: 17767919. 【124】Jia R, Hou Y, Zhang L, Li B, Zhu J. Effects of Berberine on Lipid Metabolism, Antioxidant Status, and Immune Response in Liver of Tilapia (Oreochromis niloticus) under a High-Fat Diet Feeding....

    2008 doi

  53. [62]

    【127】Feng R, Zhao ZX, Ma SR, Guo F, Wang Y, Jiang JD

    PMID: 29500098; PMCID: PMC5923433. 【127】Feng R, Zhao ZX, Ma SR, Guo F, Wang Y, Jiang JD. Gut Microbiota-Regulated Pharmacokinetics of Berberine and Active Metabolites in Beagle Dogs After Oral Administration. Front Pharmacol. 2018 Mar 21;9:214. doi: 10.3389/fphar.2018.00214. P...

    2018

  54. [63]

    【131】Jia Y, Hao C, Yang Q, Zhang W, Li G, Liu S, Hua X

    PMID: 25613587. 【131】Jia Y, Hao C, Yang Q, Zhang W, Li G, Liu S, Hua X. Inhibition of Haemophilus parasuis by berberine and proteomic studies of its mechanism of action. Res Vet Sci. 2021 Sep;138:62-68. doi: 10.1016/j.rvsc.2021.06.004. Epub 2021 Jun

    2021 doi

  55. [64]

    【132】Peng L, Kang S, Yin Z, Jia R, Song X, Li L, Li Z, Zou Y, Liang X, Li L, He C, Ye G, Yin L, Shi F, Lv C, Jing B

    PMID: 34111715. 【132】Peng L, Kang S, Yin Z, Jia R, Song X, Li L, Li Z, Zou Y, Liang X, Li L, He C, Ye G, Yin L, Shi F, Lv C, Jing B. Antibacterial activity and mechanism of berberine against Streptococcus agalactiae. Int J Clin Exp Pathol. 2015 May 1;8(5):5217-23. PMID: 261912...

    2015

  56. [65]

    【134】Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F, Yang XY, Han YX, Wang LL, Tong Q, You XF, Lin Y, Kong WJ, Si SY, Jiang JD

    PMID: 28849049. 【134】Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F, Yang XY, Han YX, Wang LL, Tong Q, You XF, Lin Y, Kong WJ, Si SY, Jiang JD. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017 ...

    2017 doi

  57. [66]

    Bacteria-Mucosal Immunity-Inflammation-Diabetes

    PMID: 28403947. 【135】Gao Z, Li Q, Wu X, Zhao X, Zhao L, Tong X. New Insights into the Mechanisms of Chinese Herbal Products on Diabetes: A Focus on the "Bacteria-Mucosal Immunity-Inflammation-Diabetes" Axis. J Immunol Res. 2017;2017:1813086. doi: 10.1155/2017/1813086. Epub 2017 Oct

    2017 doi

  58. [67]

    【136】Xie W, Gu D, Li J, Cui K, Zhang Y

    PMID: 29164155; PMCID: PMC5661076. 【136】Xie W, Gu D, Li J, Cui K, Zhang Y. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One. 2011;6(9):e24520. doi: 10.1371/journal.pone.0024520. Epub 2011 Sep

    2011 doi

  59. [68]

    【137】Wu C, Zhao Y, Zhang Y, Yang Y, Su W, Yang Y, Sun L, Zhang F, Yu J, Wang Y, Guo P, Zhu B, Wu S

    PMID: 21915347; PMCID: PMC3167861. 【137】Wu C, Zhao Y, Zhang Y, Yang Y, Su W, Yang Y, Sun L, Zhang F, Yu J, Wang Y, Guo P, Zhu B, Wu S. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decr...

    2021 doi

  60. [69]

    【139】Yang WL, Zhang CY, Ji WY, Zhao LL, Yang FY, Zhang L, Cao X

    PMID: 27898425; PMCID: PMC5644798. 【139】Yang WL, Zhang CY, Ji WY, Zhao LL, Yang FY, Zhang L, Cao X. Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction. Am J Chin Med. 2024;52(1):253-274. doi: 10.1142/S0192415X24500113....

    2024 doi

  61. [70]

    【140】Wang H, Zhang H, Gao Z, Zhang Q, Gu C

    PMID: 38351702. 【140】Wang H, Zhang H, Gao Z, Zhang Q, Gu C. The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Front Cell Infect Microbiol. 2022 Aug 25;12:854885. doi: 10.3389/fcimb.2022.854885. PMID: 36093200; PMCID: PMC9452888. 【141】Plovier H,...

    2022

  62. [71]

    【142】Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD

    PMID: 27892954. 【142】Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S ...

    2013 doi

  63. [72]

    【143】Chen Y, Hao Z, Zhao H, Duan X, Jia D, Li K, Yang Y, Cui H, Gao M, Zhao D

    PMID: 23671105; PMCID: PMC3670398. 【143】Chen Y, Hao Z, Zhao H, Duan X, Jia D, Li K, Yang Y, Cui H, Gao M, Zhao D. Berberine alleviates intestinal barrier dysfunction in glucolipid metabolism disorder hamsters by modulating gut microbiota and gut-microbiota-related tryptophan m...

    2023 doi

  64. [73]

    【144】Han J, Lin H, Huang W

    PMID: 36168925. 【144】Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit. 2011 Jul;17(7):RA164-7. doi: 10.12659/msm.881842. PMID: 21709646; PMCID: PMC3539561. 【145】Sunwoo JY, Eliasberg CD, Carballo CB, Rodeo SA. The role o...

    2011 doi

  65. [74]

    【146】Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr

    PMID: 32190920. 【146】Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003 Dec;112(12):1796-808. doi: 10.1172/JCI19246. PMID: 14679176; PMCID: PMC296995. 【147】Lumeng CN,...

    2003 doi

  66. [75]

    【150】Noh JW, Jun MS, Yang HK, Lee BC

    PMID: 30229891; PMCID: PMC6230999. 【150】Noh JW, Jun MS, Yang HK, Lee BC. Cellular and Molecular Mechanisms and Effects of Berberine on Obesity-Induced Inflammation. Biomedicines. 2022 Jul 19;10(7):1739. doi: 10.3390/biomedicines10071739. PMID: 35885044; PMCID: PMC9312506. 【151...

    2022

  67. [76]

    【152】Wu H, Zhang L, Dong X, Yang J, Zheng L, Li L, Liu X, Jin M, Zhang P

    PMID: 38986300. 【152】Wu H, Zhang L, Dong X, Yang J, Zheng L, Li L, Liu X, Jin M, Zhang P. Targeted delivery of berberine using bionic nanomaterials for Atherosclerosis therapy. Biomed Pharmacother. 2024 Sep;178:117135. doi: 10.1016/j.biopha.2024.117135. Epub 2024 Jul

    2024

  68. [77]

    【153】Lin J, Cai Q, Liang B, Wu L, Zhuang Y, He Y, Lin W

    PMID: 39047421. 【153】Lin J, Cai Q, Liang B, Wu L, Zhuang Y, He Y, Lin W. Berberine, a Traditional Chinese Medicine, Reduces Inflammation in Adipose Tissue, Polarizes M2 Macrophages, and Increases Energy Expenditure in Mice Fed a High-Fat Diet. Med Sci Monit. 2019 Jan 4;25:87-9...

    2019

  69. [78]

    【156】Zhou H, Feng L, Xu F, Sun Y, Ma Y, Zhang X, Liu H, Xu G, Wu X, Shen Y, Sun Y, Wu X, Xu Q

    PMID: 37086629; PMCID: PMC10172918. 【156】Zhou H, Feng L, Xu F, Sun Y, Ma Y, Zhang X, Liu H, Xu G, Wu X, Shen Y, Sun Y, Wu X, Xu Q. Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to in...

    2017 doi

  70. [79]

    【157】Zhang XY, Yu L, Wang K, Wang M, Li P, Zheng ZG, Yang H

    PMID: 28282788. 【157】Zhang XY, Yu L, Wang K, Wang M, Li P, Zheng ZG, Yang H. The combination of berberine and isoliquiritigenin synergistically improved adipose inflammation and obesity-induced insulin resistance. Phytother Res. 2024 Aug;38(8):3839-3855. doi: 10.1002/ptr.8233....

    2024 doi

  71. [80]

    【158】He W, Kapate N, Shields CW 4th, Mitragotri S

    PMID: 38729776. 【158】He W, Kapate N, Shields CW 4th, Mitragotri S. Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. Adv Drug Deliv Rev. 2020;165-166:15-40. doi: 10.1016/j.addr.2019.12.001. Epub 2019 Dec

    2020 doi

  72. [81]

    【159】Schultze JL, Schmieder A, Goerdt S

    PMID: 31816357. 【159】Schultze JL, Schmieder A, Goerdt S. Macrophage activation in human diseases. Semin Immunol. 2015 Aug;27(4):249-56. doi: 10.1016/j.smim.2015.07.003. Epub 2015 Aug

    2015 doi

  73. [82]

    2022 May;43(5):1285-1298

    Acta Pharmacol Sin. 2022 May;43(5):1285-1298. doi: 10.1038/s41401-021-00736-y. Epub 2021 Aug

    2022 doi

  74. [83]

    【161】Sun J, Zeng Q, Wu Z, Huang L, Sun T, Ling C, Zhang B, Chen C, Wang H

    PMID: 34417576; PMCID: PMC9061715. 【161】Sun J, Zeng Q, Wu Z, Huang L, Sun T, Ling C, Zhang B, Chen C, Wang H. Berberine inhibits NLRP3 inflammasome activation and proinflammatory macrophage M1 polarization to accelerate peripheral nerve regeneration. Neurotherapeutics. 2024 Ju...

    2024 doi

  75. [84]

    【162】Kwon S, Seok S, Yau P, Li X, Kemper B, Kemper JK

    PMID: 38570276; PMCID: PMC11067341. 【162】Kwon S, Seok S, Yau P, Li X, Kemper B, Kemper JK. Obesity and aging diminish sirtuin 1 (SIRT1)-mediated deacetylation of SIRT3, leading to hyperacetylation and decreased activity and stability of SIRT3. J Biol Chem. 2017 Oct 20;292(42):...

    2017 doi

  76. [85]

    【163】Meng G, Li P, Du X, Feng X, Qiu F

    PMID: 28808064; PMCID: PMC5655509. 【163】Meng G, Li P, Du X, Feng X, Qiu F. Berberine alleviates ulcerative colitis by inhibiting inflammation through targeting IRGM1. Phytomedicine. 2024 Oct;133:155909. doi: 10.1016/j.phymed.2024.155909. Epub 2024 Jul

    2024

  77. [86]

    【164】Mansour A, Noori M, Hakemi MS, Haghgooyan Z, Mohajeri-Tehrani MR, Mirahmad M, Sajjadi-Jazi SM

    PMID: 39068762. 【164】Mansour A, Noori M, Hakemi MS, Haghgooyan Z, Mohajeri-Tehrani MR, Mirahmad M, Sajjadi-Jazi SM. Hyperandrogenism and anthropometric parameters in women with polycystic ovary syndrome. BMC Endocr Disord. 2024 Sep 27;24(1):201. doi: 10.1186/s12902-024-01733-y...

    2024 doi

  78. [87]

    【166】Shen HR, Xu X, Li XL

    PMID: 26132930. 【166】Shen HR, Xu X, Li XL. Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. Reprod Biol Endocrinol. 2021 Jan 7;19(1):3. doi: 10.1186/s12958-020-00684-y. PMID: 33407557; PMCID...

    2021 doi

  79. [88]

    【170】Payab M, Hasani-Ranjbar S, Baeeri M, Rahimifard M, Arjmand B, Haghi-Aminjan H, Abdollahi M, Larijani B

    PMID: 34921647. 【170】Payab M, Hasani-Ranjbar S, Baeeri M, Rahimifard M, Arjmand B, Haghi-Aminjan H, Abdollahi M, Larijani B. Development of a Novel Anti-Obesity Compound with Inhibiting Properties on the Lipid Accumulation in 3T3-L1 Adipocytes. Iran Biomed J. 2020 May;24(3):15...

    2020 doi

  80. [89]

    【171】Guarino G, Strollo F, Carbone L, Della Corte T, Letizia M, Marino G, Gentile S

    PMID: 31952433; PMCID: PMC7275626. 【171】Guarino G, Strollo F, Carbone L, Della Corte T, Letizia M, Marino G, Gentile S. Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study i...

    2017

  81. [90]

    【174】Fulas OA, Laferrière A, Ayoub G, Gandrath D, Mottillo C, Titi HM, Stein RS, Friščić T, Coderre TJ

    PMID: 26948852. 【174】Fulas OA, Laferrière A, Ayoub G, Gandrath D, Mottillo C, Titi HM, Stein RS, Friščić T, Coderre TJ. Drug-Nutraceutical Co-Crystal and Salts for Making New and Improved Bi-Functional Analgesics. Pharmaceutics. 2020 Nov 26;12(12):1144. doi: 10.3390/pharmaceut...

    2020 doi

  82. [91]

    【179】Xu H, Li S, Liu YS

    PMID: 21690347; PMCID: PMC3131364. 【179】Xu H, Li S, Liu YS. Nanoparticles in the diagnosis and treatment of vascular aging and related diseases. Signal Transduct Target Ther. 2022 Jul 11;7(1):231. doi: 10.1038/s41392-022-01082-z. PMID: 35817770; PMCID: PMC9272665. 【180】Hu CM, ...

    2022 doi

  83. [92]

    【181】Piao JG, Wang L, Gao F, You YZ, Xiong Y, Yang L

    PMID: 26374997; PMCID: PMC4871317. 【181】Piao JG, Wang L, Gao F, You YZ, Xiong Y, Yang L. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano. 2014 Oct 28;8(10):10414-...

    2014 doi

  84. [93]

    【182】Liu Y, Luo J, Chen X, Liu W, Chen T

    PMID: 25286086. 【182】Liu Y, Luo J, Chen X, Liu W, Chen T. Cell Membrane Coating Technology: A Promising Strategy for Biomedical Applications. Nanomicro Lett. 2019 Nov 16;11(1):100. doi: 10.1007/s40820-019-0330-9. PMID: 34138027; PMCID: PMC7770915. 【183】Rao L, Bu LL, Cai B, Xu ...

    2019 doi

  85. [94]

    【184】Xu HY, Liu CS, Huang CL, Chen L, Zheng YR, Huang SH, Long XY

    PMID: 26970518. 【184】Xu HY, Liu CS, Huang CL, Chen L, Zheng YR, Huang SH, Long XY. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge. Colloids Surf B Biointerfaces. 2019 Sep 1;181:927-934. doi: 10.1016/j.colsurfb.2019.06.006....

    2019 doi

  86. [95]

    【185】Mirhadi E, Rezaee M, Malaekeh-Nikouei B

    PMID: 31382342. 【185】Mirhadi E, Rezaee M, Malaekeh-Nikouei B. Nano strategies for berberine delivery, a natural alkaloid of Berberis. Biomed Pharmacother. 2018 Aug;104:465-473. doi: 10.1016/j.biopha.2018.05.067. Epub 2018 May

    2018 doi

  87. [96]

    【186】Glassman PM, Villa CH, Ukidve A, Zhao Z, Smith P, Mitragotri S, Russell AJ, Brenner JS, Muzykantov VR

    PMID: 29793179. 【186】Glassman PM, Villa CH, Ukidve A, Zhao Z, Smith P, Mitragotri S, Russell AJ, Brenner JS, Muzykantov VR. Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics. Pharmaceutics. 2020 May 9;12(5):440. doi: 10.339...

    2020

  88. [97]

    【190】Li QP, Dou YX, Huang ZW, Chen HB, Li YC, Chen JN, Liu YH, Huang XQ, Zeng HF, Yang XB, Su ZR, Xie JH

    PMID: 38909786. 【190】Li QP, Dou YX, Huang ZW, Chen HB, Li YC, Chen JN, Liu YH, Huang XQ, Zeng HF, Yang XB, Su ZR, Xie JH. Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. Phytomedicine. 2021 May;85:153550. doi: 10.1016/j.phymed.2021.153550. E...

    2021

  89. [98]

    【191】Khvostov MV, Gladkova ED, Borisov SA, Fedotova MS, Zhukova NA, Marenina MK, Meshkova YV, Luzina OA, Tolstikova TG, Salakhutdinov NF

    PMID: 33831691. 【191】Khvostov MV, Gladkova ED, Borisov SA, Fedotova MS, Zhukova NA, Marenina MK, Meshkova YV, Luzina OA, Tolstikova TG, Salakhutdinov NF. Study of Hypoglycemic Activity of Novel 9-N-alkyltetrahydroberberine Derivatives. Int J Mol Sci. 2022 Nov 16;23(22):14186. ...

    2022

  90. [99]

    【194】Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM

    PMID: 31401380. 【194】Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients. 2021 Dec 28;14(1):124. doi: 10.3390/nu14010...

    2021 doi

  91. [2024]

    【4】Ilyas Z, Perna S, Al-Thawadi S, Alalwan TA, Riva A, Petrangolini G, Gasparri C, Infantino V, Peroni G, Rondanelli M

    https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2024. 【4】Ilyas Z, Perna S, Al-Thawadi S, Alalwan TA, Riva A, Petrangolini G, Gasparri C, Infantino V, Peroni G, Rondanelli M. The effect of Berberine on weight loss in order to prevent obesity: A syste...

    2024

Pith tools

Reviewed August 10, 2026 · model on record in the stance chip above.